the best chance at measuring the signal and to be able to get the best sensitivity from that. So one of the ways you do that is to give a dose that's large enough to give a good signal, if you're measuring in plasma or any other bioassay.
Endogenous baseline, as I mentioned before, feedback inhibition is always something that you need to deal with as an issue. Different variations or circadian rhythms, what you saw illustrated, and whether it has linear or nonlinear pharmacokinetics.
So again, I feel like I harp on this endlessly, but again, the core question in bioequivalence is one of formulation. So you have to always keep that in mind, that you're really looking at how that manufacturer has made their formulation and how the results of that work actually perform when it gets into the in vivo situation. Sometimes we lose track of that core question with other very legitimate clinical concerns about how this is used and how the drug or drug product actually works.
But the BE question is a very simple and should be a very directed one on what is the best way of